Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia E Maxson

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Cancer Research|October 24, 2018
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in LeukemiaDavid R Spiciarich, Stephen T Oh, Amy Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Blood Advances|January 8, 2025
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiationLucie Darmusey, Anna J Bagley, Thai T Nguyen, et al.
Molecular Cancer Research : MCR|March 28, 2023
Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid LeukemiaWilliam M Yashar, Brittany M Curtiss, Daniel J Coleman, et al.
Leukemia|December 16, 2022
Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitorsTheodore P Braun, Joseph Estabrook, Zachary Schonrock, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemiaHanqian L Carlson, Thai T Nguyen, Samantha Tauchmann, et al.
Blood Cancer Discovery|April 19, 2026
MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemiaHanqian L Carlson, Thai T Nguyen, Samantha Tauchmann, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadeWilliam M Yashar, Itallia V Pacentine, Akram Taherinasab, et al.
Leukemia|May 19, 2022
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemiaBrittany M Curtiss, Jake VanCampen, Jommel Macaraeg, et al.
Cancer Research|December 19, 2015
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisJulia E Maxson, Melissa L Abel, Jinhua Wang, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Cancer Research|October 24, 2018
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in LeukemiaDavid R Spiciarich, Stephen T Oh, Amy Foley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618IJulia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Blood Advances|January 8, 2025
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiationLucie Darmusey, Anna J Bagley, Thai T Nguyen, et al.
Molecular Cancer Research : MCR|March 28, 2023
Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid LeukemiaWilliam M Yashar, Brittany M Curtiss, Daniel J Coleman, et al.
Leukemia|December 16, 2022
Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitorsTheodore P Braun, Joseph Estabrook, Zachary Schonrock, et al.
Biorxiv : the Preprint Server for Biology|January 16, 2026
MYST acetyltransferases are a targetable therapeutic vulnerability in SETBP1-mutant leukemiaHanqian L Carlson, Thai T Nguyen, Samantha Tauchmann, et al.
Blood Cancer Discovery|April 19, 2026
MYST acetyltransferases interact with SETBP1 and are a targetable therapeutic vulnerability in SETBP1-mutant leukemiaHanqian L Carlson, Thai T Nguyen, Samantha Tauchmann, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadeWilliam M Yashar, Itallia V Pacentine, Akram Taherinasab, et al.
Leukemia|May 19, 2022
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemiaBrittany M Curtiss, Jake VanCampen, Jommel Macaraeg, et al.
Cancer Research|December 19, 2015
Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic AnalysisJulia E Maxson, Melissa L Abel, Jinhua Wang, et al.
Pageof 5